Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

This legislation aims to extend the Accelerating Access to Critical Therapies for ALS Act, a law designed to speed up the development of treatments for Amyotrophic Lateral Sclerosis (ALS) and other rare neurodegenerative diseases. By reauthorizing these provisions through 2031, the bill would ensure continued federal support for grant programs that fund research into new therapies and provide patients with earlier access to experimental drugs that are still in the clinical trial phase. If enacted, the bill would provide long-term stability for researchers and healthcare providers working to combat ALS. For patients and their families, this could mean a sustained federal commitment to finding a cure and expanded opportunities to participate in specialized treatment programs. The proposal focuses on maintaining the infrastructure necessary to move medical breakthroughs from the laboratory to the pharmacy more quickly.